Venous and arterial thrombosis: Epidemiology and risk factors at various ages

Maturitas

Volumn 47, Issue 4, 2004, Pages 259-263

  Lowe, Gordon D O ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Epidemiology; Risk factors; Thrombosis

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; ESTROGEN; GESTAGEN; HOMOCYSTEINE; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAMOXIFEN; TRIACYLGLYCEROL;

ACUTE DISEASE; ARTERY THROMBOSIS; ATHEROSCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HAZARD ASSESSMENT; HEART INFARCTION; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; IMMOBILIZATION; INCIDENCE; INFLAMMATION; INJURY; ISCHEMIC HEART DISEASE; META ANALYSIS; OBESITY; POPULATION RESEARCH; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PREVALENCE; RISK FACTOR; SEX DIFFERENCE; SMOKING HABIT; STROKE; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CONTRACEPTIVES, ORAL, COMBINED; ESTROGEN REPLACEMENT THERAPY; FEMALE; GREAT BRITAIN; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS;

EID: 1942504150     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2003.12.009     Document Type: Conference Paper

References (23)

1. Smeeth L., Haines A., Ebrahim S. Numbers needed to treat derived from meta-analyses - sometimes informative, usually misleading. BMJ. 318:1999;1548-1551.
2. Wannamethee S.G., Lowe G.D.O., Whincup P.H., Rumley A., Walker M., Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation. 105:2002;1785-1790.
3. Woodward M., Rumley A., Lowe G.D.O., Tunstall-Pedoe H. C-reactive protein: associations with haematological variables, cardiovascular risk factors, and prevalent cardiovascular disease. Br. J. Haematol. 121:2003;135-141.
4. Lowe G.D.O., Rumley A., Woodward M., Morrison C.E., Philippou H., Lane D.A.et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br. J. Haematol. 97:1997;775-784.
5. Woodward M., Rumley A., Tunstall-Pedoe H., Lowe G.D.O. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br. J. Haematol. 104:1999;246-257.
6. Lowe G.D.O., Rumley A., Woodward M., Reid E., Rumley J. Activated protein C resistance and the FV: R506Q mutation in a random population sample: associations with cardiovascular risk factors and coagulation variables. Thromb. Haemost. 81:1999;918-924.
7. Rosendaal F.R., Helmerhorst F.M., Vandenbroucke J.P. Female hormones and thrombosis. Arterioscler. Thromb. Vasc. Biol. 22:2002;201-210.
8. Beral V., Banks E., Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 360:2002;942-944.
9. Prophylaxis of venous thromboembolism. A national clinical guideline. (SIGN guideline 62) Scottish Intercollegiate Guidelines Network (SIGN), Edinburgh, 2002.
10. Vandenbroucke J.P., van der Meer F.J.M., Helmerhorst F.M., Rosendaal F.R. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ. 313:1996;1127-1130.
11. Rosendaal F.R., Vessey M., Rumley A., Daly E., Woodward M., Helmerhorst F.M.et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br. J. Haematol. 116:2002;851-854.
12. Rich-Edwards W. The primary prevention of coronary heart disease in women. N. Engl. J. Med. 332:1995;1758-1766.
13. Burchfield C.M., Laws A., Benfante R., Goldberg R.J., Hwang L.-J., Chiu D.et al. Combined effects of HDL cholesterol, triglycerides, and total cholesterol concentrations on 18-year risk of atherosclerotic disease. Circulation. 92:1995;1430-1436.
14. Danesh J., Collins R., Peto R., Lowe G.D.O. Haematocrit, viscosity, erthryocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur. Heart J. 21:2000;515-520.
15. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet. 351:1998;1425-1427.
16. Blake J.M., Collins J.A., Reid R.L., Fedorkow D.M., Lalonde A.B. The SOGC statement on the WHI report on estrogen and progestin use in postmenopausal women. J. Obstet. Gynaecol. Can. 24:2002;783-787.
17. Tunstall-Pedoe H., Kuylasmaa K., Amouyel P., Arveiller D., Rajakangas A., Pajak A. Myocardial infarction and coronary deaths in the World Health Organisation MONICA project. Circulation. 90:1994;583-612.
18. Tunstall-Pedoe H., Woodward M., Tavendale P., Brook R.A., McCluskey M.K. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. BMJ. 315:1997;722-729.
19. Jonsdottir L.S., Sigfusson N., Guonason V., Sigvaldason H., Thorgeirsson G. Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J. Cardiovasc. Risk. 9:2002;67-76.
20. Wood D., Durrington P., Poulter N., McInnes G., Rees A., Wray R. on behalf of the British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, and British Diabetic Association Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart. 80(Suppl. 2):1999;s1-s29.
21. Pradhan A.D., Manson J.E., Rossouw J.E., Siscovick D.S., Mouton C.P., Rifai N.et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease. Prospective analysis from the Women's Health Initiative Observational Study. JAMA. 288:2002;980-987.
22. Lowe G.D.O. Hormone replacement therapy: prothrombotic vs. protective effects. J. Pathophysiol. Haemost. Thromb. 32:2003;329-332.
23. Scarabin P.Y., Oger E., Plu-Burea G. on behalf of the Estrogen and ThromboEmbolism Risk (ESTHER) Study Group Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 362:2003;428-432.